Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | KCNB1 | Q14721 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6567749 | 0.85 | HTT (0.54) | RAB9AMAPTHTTKMT2A | |
| SCHEMBL6566811 | 0.83 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2ALOX15GLA | |
| SCHEMBL6567998 | 0.83 | L3MBTL1 (0.53) | NPC1RAB9ASMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL6567969 | 0.81 | CASR (0.53) | KMT2A | |
| SCHEMBL6567876 | 0.81 | RAF1 (0.44) | SMN1; SMN2MAPTHTTKMT2A | |
| SCHEMBL6567243 | 0.80 | ALDH1A1 (0.53) | RAB9ASMN1; SMN2ALOX15MAPTHTT | |
| SCHEMBL6565928 | 0.80 | MCHR1 (0.46) | SMN1; SMN2KMT2A | |
| SCHEMBL6568066 | 0.80 | EPHX1 (0.49) | NPC1RAB9ASMN1; SMN2MAPTKMT2A | |
| SCHEMBL6566515 | 0.80 | NAMPT (0.52) | RAB9ASMN1; SMN2MAPTHTTKMT2A | |
| SCHEMBL6566625 | 0.79 | PPARA (0.52) | SMN1; SMN2MAPTKMT2AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | NPC1 3521/4885RAB9A 1322/4885SMN1; SMN2 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.